This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Molecular Templates Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Craig Jalbert

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Analyseartikel • Oct 10

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Molecular Templates, Inc. ( NASDAQ:MTEM ) shares have had a really impressive month, gaining 30% after a shaky period...

Analyseartikel • Aug 17

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Molecular Templates, Inc. ( NASDAQ:MTEM ) just released its latest second-quarter report and things are not looking...

Analyseartikel • Jul 30

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Those holding Molecular Templates, Inc. ( NASDAQ:MTEM ) shares would be relieved that the share price has rebounded 27...

Analyseartikel • Apr 03

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders that were waiting for something to happen have been dealt a blow...

Analyseartikel • Dec 20

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Unfortunately for some shareholders, the Molecular Templates, Inc. ( NASDAQ:MTEM ) share price has dived 26% in the...

Analyseartikel • Apr 17

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Molecular Templates, Inc. ( NASDAQ:MTEM ) shares have had a really impressive month, gaining 45% after a shaky period...

Analyseartikel • Nov 16

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Market forces rained on the parade of Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders today, when the analysts...

Analyseartikel • Aug 14

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

The latest analyst coverage could presage a bad day for Molecular Templates, Inc. ( NASDAQ:MTEM ), with the analysts...

Seeking Alpha • Aug 11

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Molecular Templates press release (NASDAQ:MTEM): Q2 GAAP EPS of -$0.44 misses by $0.01. Revenue of $4.42M (-70.8% Y/Y) misses by $2.6M. As of June 30, 2022, MTEM’s cash and investments totaled $104.4M. MTEM’s current cash and investments are expected to fund operations to the end of 2023.

Analyseartikel • Apr 29

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyseartikel • Dec 30

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyseartikel • Nov 25

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

One thing we could say about the analysts on Molecular Templates, Inc. ( NASDAQ:MTEM ) - they aren't optimistic, having...

Geschäftsführer

Craig Jalbert

no data

Amtszeit

Craig Jalbert is President, Chief Executive Officer and Chief Financial Officer of Molecular Templates, Inc.

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/07/21 23:28
Aktienkurs zum Tagesende	2025/07/21 00:00
Gewinne	2024/06/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Molecular Templates, Inc. wird von 8 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Carter Gould	Barclays
Tazeen Ahmad	BofA Global Research
Roger Song	Jefferies LLC

This company listing is no longer active

Molecular Templates Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Molecular Templates, Inc. Announces Chief Financial Officer Changes

Molecular Templates, Inc., Annual General Meeting, Sep 27, 2024

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Announces Board Changes

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

Recent updates

Molecular Templates, Inc. announced that it expects to receive $250 million in funding

Interim DIP Financing Approved for Molecular Templates, Inc.

Motion for Joint Administration Approved for Molecular Templates, Inc.

Molecular Templates, Inc. Filed for Bankruptcy

Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from S&P TMI Index

Molecular Templates, Inc.(OTCPK:MTEM) dropped from NASDAQ Composite Index

Molecular Templates, Inc. Provides Nasdaq Non-Compliance Update

Molecular Templates, Inc. Announces Chief Financial Officer Changes

Molecular Templates Receives Non-Compliance Letters from Nasdaq

Molecular Templates, Inc. announced delayed 10-Q filing

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Molecular Templates, Inc., Annual General Meeting, Sep 27, 2024

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting

Consensus revenue estimates decrease by 44%, EPS upgraded

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Market cap size

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Molecular Templates, Inc. Announces Board Changes

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Consensus revenue estimates increase by 16%

New major risk - Financial position

Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

New major risk - Revenue and earnings growth

Molecular Templates Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Molecular Templates, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

Molecular Templates, Inc. announced that it expects to receive $40.044 million in funding from BVF Partners L.P., Adage Capital Management, L.P., Bellevue Asset Management AG

New major risk - Financial position

Consensus revenue estimates decrease by 16%, EPS upgraded

Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Price target decreased by 67% to US$3.50

Consensus revenue estimates increase by 384%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Consensus revenue estimates decrease by 34%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 22% to US$10.13

Insufficient new directors

Consensus revenue estimates increase by 13%

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$10.13

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Price target decreased to US$9.33

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Price target decreased to US$10.92

Consensus forecasts updated

Price target decreased to US$10.92

Price target decreased to US$11.25

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind